Richard Canters

Richard Canters

Auto-generated profile, based on publicly available information

Richard Canters

Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Radiotherapy and Oncology
Verified
Journal Article
Open access
LKLaura Patricia Kaplan
Laura Patricia Kaplan
LPLorenzo Placidi
Lorenzo Placidi
ABAnna Bäck
Anna Bäck
RCRichard Canters
Richard Canters
MHMohammad Hussein
Mohammad Hussein
LWLamberto Widesott
Lamberto Widesott
Plan complexity and robustness are two essential aspects of treatment plan quality but there is a great variability in their management in clinical practice. This study reports the results of the 2020 ESTRO survey on plan complexity and robustness to identify needs and guide future discussions and consensus. A survey was distributed online to ESTRO members. Plan complexity was defined as the modulation of machine parameters and increased uncertainty in dose calculation and delivery. Robustness was defined as a dose distribution's sensitivity towards errors stemming from treatment uncertainties, patient setup, or anatomical changes. A total of 126 radiotherapy centres from 33 countries participated, 95 of them (75%) from Europe and Central Asia. The majority controlled and evaluated plan complexity using monitor units (56 centres) and aperture shapes (38 centres). To control robustness, 98 (97% of question responses) photon and 5 (50%) proton centres used PTV margins for plan optimization while 75 (94%) and 5 (50%), respectively, used margins for plan evaluation. Seventeen (21%) photon and 8 (80%) proton centres used robust optimisation, while 10 (13%) and 8 (80%), respectively, used robust evaluation. Primary uncertainties considered were patient setup (photons and protons) and range calculation uncertainties (protons). Participants expressed the need for improved commercial tools to control and evaluate plan complexity and robustness. Clinical implementation of methods to control and evaluate plan complexity and robustness is very heterogeneous. Better tools are needed to manage complexity and robustness in treatment planning systems. International guidelines may promote harmonization.

17 June 2023 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
VTVicki Trier Taasti
Vicki Trier Taasti
DHDjoya Hattu
Djoya Hattu
SPStephanie Peeters
Stephanie Peeters
ASAnke van der Salm
Anke van der Salm
JLJudith van Loon
Judith van Loon
RCRichard Canters
Richard Canters
Efficient workflows for adaptive proton therapy are of high importance. This study evaluated the possibility to replace repeat-CTs (reCTs) with synthetic CTs (sCTs), created based on cone-beam CTs (CBCTs), for flagging the need of plan adaptations in intensity-modulated proton therapy (IMPT) treatment of lung cancer patients. Forty-two IMPT patients were retrospectively included. For each patient, one CBCT and a same-day reCT were included. Two commercial sCT methods were applied; one based on CBCT number correction (Cor-sCT), and one based on deformable image registration (DIR-sCT). The clinical reCT workflow (deformable contour propagation and robust dose re-computation) was performed on the reCT as well as the two sCTs. The deformed target contours on the reCT/sCTs were checked by radiation oncologists and edited if needed. A dose-volume-histogram triggered plan adaptation method was compared between the reCT and the sCTs; patients needing a plan adaptation on the reCT but not on the sCT were denoted false negatives. As secondary evaluation, dose-volume-histogram comparison and gamma analysis (2%/2mm) were performed between the reCT and sCTs. There were five false negatives, two for Cor-sCT and three for DIR-sCT. However, three of these were only minor, and one was caused by tumour position differences between the reCT and CBCT and not by sCT quality issues. An average gamma pass rate of 93% was obtained for both sCT methods. Both sCT methods were judged to be of clinical quality and valuable for reducing the amount of reCT acquisitions.

1 October 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
FVFemke Vaassen
Femke Vaassen
CHColien Hazelaar
Colien Hazelaar
RCRichard Canters
Richard Canters
SPStephanie Peeters
Stephanie Peeters
SPSteven Petit
Steven Petit
WEWouter van Elmpt
Wouter van Elmpt
Quality of automatic contouring is generally assessed by comparison with manual delineations, but the effect of contour differences on the resulting dose distribution remains unknown. This study evaluated dosimetric differences between treatment plans optimized using various organ-at-risk (OAR) contouring methods. OARs of twenty lung cancer patients were manually and automatically contoured, after which user-adjustments were made. For each contour set, an automated treatment plan was generated. The dosimetric effect of intra-observer contour variation and the influence of contour variations on treatment plan evaluation and generation were studied using dose-volume histogram (DVH)-parameters for thoracic OARs. Dosimetric effect of intra-observer contour variability was highest for Heart Dmax (3.4 ± 6.8 Gy) and lowest for Lungs-GTV Dmean (0.3 ± 0.4 Gy). The effect of contour variation on treatment plan evaluation was highest for Heart Dmax (6.0 ± 13.4 Gy) and Esophagus Dmax (8.7 ± 17.2 Gy). Dose differences for the various treatment plans, evaluated on the reference (manual) contour, were on average below 1 Gy/1%. For Heart Dmean, higher dose differences were found for overlap with PTV (median 0.2 Gy, 95% 1.7 Gy) vs. no PTV overlap (median 0 Gy, 95% 0.5 Gy). For Dmax-parameters, largest dose difference was found between 0-1 cm distance to PTV (median 1.5 Gy, 95% 4.7 Gy). Dose differences arising from automatic contour variations were of the same magnitude or lower than intra-observer contour variability. For Heart Dmean, we recommend delineation errors to be corrected when the heart overlaps with the PTV. For Dmax-parameters, we recommend checking contours if the distance is close to PTV (<5 cm). For the lungs, only obvious large errors need to be adjusted.

14 May 2022 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
FVFemke Vaassen
Femke Vaassen
DBDjamal Boukerroui
Djamal Boukerroui
PLPadraig Looney
Padraig Looney
RCRichard Canters
Richard Canters
KVKarolien Verhoeven
Karolien Verhoeven
WEWouter van Elmpt
Wouter van Elmpt
User-adjustments after deep-learning (DL) contouring in radiotherapy were evaluated to get insight in real-world editing during clinical practice. This study assessed the amount, type and spatial regions of editing of auto-contouring for organs-at-risk (OARs) in routine clinical workflow for patients in the thorax region. A total of 350 lung cancer and 362 breast cancer patients, contoured between March 2020 and March 2021 using a commercial DL-contouring method followed by manual adjustments were retrospectively analyzed. Subsampling was performed for some OARs, using an inter-slice gap of 1–3 slices. Commonly-used whole-organ contouring assessment measures were calculated, and all cases were registered to a common reference shape per OAR to identify regions of manual adjustment. Results were expressed as the median, 10th-90th percentile of adjustment and visualized using 3D renderings. Per OAR, the median amount of editing was below 1 mm. However, large adjustments were found in some locations for most OARs. In general, enlarging of the auto-contours was needed. Subsampling DL-contours showed less adjustments were made in the interpolated slices compared to simulated no-subsampling for these OARs. The real-world performance of automatic DL-contouring software was evaluated and proven useful in clinical practice. Specific regions-of-adjustment were identified per OAR in the thorax region, and separate models were found to be necessary for specific clinical indications different from training data. This analysis showed the need to perform routine clinical analysis especially when procedures or acquisition protocols change to have the best configuration of the workflow.

24 June 2024 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
RCRichard Canters
Richard Canters
KKKim van der Klugt
Kim van der Klugt
VTVicki Trier Taasti
Vicki Trier Taasti
JBJeroen Buijsen
Jeroen Buijsen
BTBastiaan Ta
Bastiaan Ta
MBMaaike Berbee
Maaike Berbee

9 February 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
PSPratik Samant
Pratik Samant
DRDirk de Ruysscher
Dirk de Ruysscher
FHFrank Hoebers
Frank Hoebers
RCRichard Canters
Richard Canters
EHEmma Hall
Emma Hall
FHFrank Van Den Heuvel
Frank Van Den Heuvel
A popular Normal tissue Complication (NTCP) model deployed to predict radiotherapy (RT) toxicity is the Lyman-Burman Kutcher (LKB) model of tissue complication. Despite the LKB model's popularity, it can suffer from numerical instability and considers only the generalized mean dose (GMD) to an organ. Machine learning (ML) algorithms can potentially offer superior predictive power of the LKB model, and with fewer drawbacks. Here we examine the numerical characteristics and predictive power of the LKB model and compare these with those of ML. Both an LKB model and ML models were used to predict G2 Xerostomia on patients following RT for head and neck cancer, using the dose volume histogram of parotid glands as the input feature. Model speed, convergence characteristics and predictive power was evaluated on an independent training set. We found that only global optimization algorithms could guarantee a convergent and predictive LKB model. At the same time our results showed that ML models remained unconditionally convergent and predictive, while staying robust to gradient descent optimization. ML models outperform LKB in Brier score and accuracy but compare to LKB in ROC-AUC. We have demonstrated that ML models can quantify NTCP better than or as well as LKB models, even for a toxicity that the LKB model is particularly well suited to predict. ML models can offer this performance while offering fundamental advantages in model convergence, speed, and flexibility, and so could offer an alternative to the LKB model that could potentially be used in clinical RT planning decisions.